4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Ipca Laboratories Limited (IPCALAB) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 17,210 employees. Its market capitalization is roughly ₹510 billion. In the fiscal year ended 2026-03-31, IPCALAB reported ₹95.6B in revenue and ₹11.4B in net income.
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue | ₹95.6B | ₹88.5B | ₹76.2B | ₹62.1B | — |
| Gross Profit | ₹65.8B | ₹59.2B | ₹49.0B | ₹38.0B | — |
| Operating Income (EBIT) | ₹16.3B | ₹13.6B | ₹9.3B | ₹7.0B | — |
| Net Income | ₹11.4B | ₹7.4B | ₹5.5B | ₹4.7B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Total Revenue | ₹27.9B | ₹23.9B | ₹23.9B | ₹25.6B | ₹23.1B | — | — |
| Gross Profit | ₹19.9B | ₹17.0B | ₹17.3B | ₹17.7B | ₹16.2B | — | — |
| Operating Income (EBIT) | ₹5.6B | ₹3.8B | ₹4.3B | ₹4.4B | ₹3.2B | — | — |
| Net Income | ₹4.0B | ₹3.0B | ₹3.3B | ₹2.8B | ₹2.3B | — | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Dividends Paid | (₹524M) | (₹1.0B) | (₹507M) | (₹1.0B) | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | ₹123.7B | ₹117.6B | ₹111.0B | ₹86.3B | — |
| Total Liabilities | ₹28.5B | ₹33.7B | ₹33.7B | ₹27.1B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IPCALAB viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms